Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy

International Journal of Radiation Oncology Biology Physics

Volumn 36, Issue 3, 1996, Pages 641-648

  Blackstock, A William ^a,b   Kwock, Lester ^a   Branch, Craig ^a   Zeman, Elaine M ^a   Tepper, Joel E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

5 Fluorouracil; 19F; NMR spectroscopy

Indexed keywords

FLOXURIDINE; FLUOROURACIL;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER RADIOTHERAPY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG CLEARANCE; DRUG UPTAKE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RADIATION DOSE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; FLUOROURACIL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; NEOPLASMS; RATS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0030272199     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00356-2     Document Type: Article

References (32)

1. 31P NMR spectroscopy of the energy metabolism of malignant tumor in rats during treatment. Radiother. Oncol. 21:48-52; 1991.
2. 2. Bagshaw, M. A. Possible role of potentiators in radiation therapy. AJR 85:822-833; 1961.
3. 3. Berry, R. J. Effects of some metabolic inhibitors on x-ray dose response curves for the survival of mammalian cells in vitro, and on early recovery between fractionated x-ray doses. Br. J. Radiol. 39:458-463; 1966.
4. 4. Blackstock, A.; Zeman, E.; Kwock, L.; Tepper, J. Using nuclear magnetic resonance techniques to observe the tumor metabolism of 5-fluorouracil in vivo (abstr). Proc. AAMP 1993:15.
5. 5. Byfield, J. E.; Calabro-Jones, P.; Klisak, I.; Kulhanian, F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x-rays. Int. J. Radiat. Oncol. Biol. Phys. 8:1923-1933; 1982.
6. 6. Heidelberger, C.; Chaudhuri, P. D.; Mooren, D.; Reitmeier, R. J.; Holbrook, M. A. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663-666; 1957.
7. 7. Heidelberger, C.; Griesbach, L.; Montag, B. J.; Mooren, D.; Cruz, O.; Schnitzer, R. J.; Grunberg, E. Studies on fluorinated pyrimidines. II. Effects of transplanted tumors. Cancer Res. 18:305-317; 1958.
8. 8. Hughes, L. L.; Luengas, J.; Rich, T. A.; Murray, D. Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil: Effects on cell survival, DNA repair, and cell recovery. Int. J. Radiat. Oncol. Biol. Phys. 23:983-991; 1992.
9. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res. 48:1680-1688; 1988.
10. 19F-NMR spectroscopy. Magn. Res. Med. 19:113-123; 1991.
11. 11. Krook, J. E.; Moertel, C. G.; Gunderson, L. L.; Wiedand, R. T.; Collins, R. T.; Beart, R. W.; Kubista, T. P.; Poon, M. A.; Meyers, W. C.; Mailliard, J. A. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324:709-715; 1991.
12. 12. Lawrence, T. S.; Davis, M. A.; Maybaum, J. Fluoropyrimidines as radiation sensitizers. Semin. Radiat. Oncol. 3:20-28; 1993.
13. 13. Lo, T. C.; Wiley, A. L.; Ansfield, F. J.; Brandenburg, J. H.; Davis, H. L.; Gollin, F. F.; Johnson, R. O.; Ramirez, G.; Vermund, H. Combined radiation therapy and 5-flourouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx. A randomized study. AJR 126:229-235; 1976.
14. 14. Looney, W. B.; Schaffner, J. G.; Trefil, J. S.; Kovacs, C. J.; Hopkins, H. A. Solid tumour models for the assessment of different treatment modalities: IV. The combined effects of radiation and 5-fluorouracil. Br. J. Cancer 34:254-261; 1976.
15. 15. Malet-Martino, M. C.; Faure, F.; Vialaneix, J. P.; Palevody, C.; Hollande, E.; Martino, R. Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. Cancer Chemother. Pharmacol. 18:5-10; 1986.
16. 16. Malet-Martino, M. C.; Martino, R.; Lopez, A.; Beteille, J. P.; Bon, M.; Bernadou, J.; Armand, J. P. New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR. Cancer Chemother. Pharmacol. 13:31-35; 1984.
17. 17. McSheehy, P. M. J.; Prior, M. J. W.; Griffiths, J. R. Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br. J. Cancer 60:303-309; 1989.
18. 18. Miller, E. M.; Kinsella, T. J. Radiosensitization by fluorodeoxyuridine: Effects on thymidylate synthase inhibition and cell synchronization. Cancer Res. 52:1687-1694; 1992.
19. 19. Moertel, C.; Childs, D.; O'Fallon, J.; Holbrook, M. A.; Schutt, A. J.; Reitemeir, R. J. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J. Clin. Oncol. 2:1249-1254; 1984.
20. 20. Nakajima, Y.; Miyamoto, T.; Tanabe, M.; Watanabe, I.; Terasima, T. Enhancement of mammalian cell killing by 5-fluorouracil in combination with x-rays. Cancer Res. 39:3763-3767; 1979.
21. 19F-NMR for monitoring 5-fluorouracil chemotherapy. J. Cancer Res. Clin. Oncol. 117:295-304; 1991.
22. 19F NMR spectroscopy of the antimetabolite 5-fluorouracil and its analogues. An assessment of drug metabolism. Biochem. Pharmacol. 39:857-863; 1990.
23. 19F MR spectroscopy. Radiology 174:141-145; 1990.
24. 19F Magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. Cancer Res. 51:1384-1390; 1991.
25. 19F-NMR. Br. J. Cancer 50:113-119; 1984.
26. 26. Tang, H.; Davis, M. A.; Strickfaden, S. M.; Maybaum, J.; Lawrence, T. S. Influence of cell cycle phase on radiation-induced cytotoxicity and DNA damage in human colon cancer (HT-29) and Chinese hamster ovary cells. Radiat. Res. 138(Suppl. 1):S109-S112; 1994.
27. 27. The Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N. Engl. J. Med. 312:1465-1472; 1985.
28. 28. The Gastrointestinal Tumor Study Group Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48:1705-1710; 1981.
29. 29. Vietti, T.; Eggerding, F.; Valeriote, F. Combined effect of X radiation on 5-fluorouracil on survival of transplanted leukemic cells. J. Natl. Cancer Inst. 47:865-870; 1971.
30. 30. Weinberg, M. J.; Rauth, A. M. 5-FluorouraciI infusions and fractionated doses of radiation: Studies with a murine squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 13:1691-1699; 1987.
31. 31. Weinberg, M.; Lapointe, T.; Rauth, A. Growth delay in a murine squamous cell tumor after local radiation and concurrent infusional 5-fluorouracil treatment. Int. J. Radiat. Oncol. Biol. Phys. 12:1449-1452; 1986.
32. 32. Wolf, W.; Albright, M. J.; Silver, M. S.; Weber, H.; Reichardt, U.; Sauer, R. Fluorine-19 NMR spectroscopy studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn. Res. Imag. 5:165-169; 1987.